Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy
Oncology Research · 2024 · 32 (1) · 49-60
DOI: 10.32604/or.2023.042383 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Research, 2024. Verfasst von Qiuqiang Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Translational Medicine, The First Affiliated Hospital, Huzhou University School of Medicine, Huzhou, 313000, China. Hauptthemen laut MEDLINE: CD47 Antigen, Neoplasms. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Translational Medicine, The First Affiliated Hospital, Huzhou University School of Medicine, Huzhou, 313000, China.
- Department of Hematology, Puyang Youtian General Hospital, Puyang, 457001, China.
- Department of Medicine, Moores Cancer Center, Sanford Stem Cell Institute, University of California San Diego, La Jolla, San Diego, 92093, USA.
Zitieren
APA
Chen, Q., Guo, X., & Ma, W. (2024). Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy. Oncology Research, 32(1), 49-60. https://doi.org/10.32604/or.2023.042383
Vancouver
Chen Q, Guo X, Ma W. Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy. Oncology Research. 2024;32(1):49-60. doi:10.32604/or.2023.042383
BibTeX
@article{Chen2024,
author = {Chen, Qiuqiang and Guo, Xuejun and Ma, Wenxue},
title = {Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy},
journal = {Oncology Research},
year = {2024},
volume = {32},
number = {1},
pages = {49--60},
doi = {10.32604/or.2023.042383}
}
EUVIMED